International Clinical Trial: A Prospective, Single-Arm Study of Nimotuzumab plus Camrelizumab, Irinotecan Liposome (II) and Raltitrexed as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119939) titled 'A Prospective, Single-Arm Study of Nimotuzumab plus Camrelizumab, Irinotecan Liposome (II) and Raltitrexed as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer' on March 5.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Chongqing Medical University First Affiliated Hospital

Condition: Pancreatic cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-03-05

Target Sample Size: Experimental Group:42;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=308245

Published by HT D...